Immune reconstitution disease associated with parasitic infections following initiation of antiretroviral therapy

Current Opinion in Infectious Diseases

Volumn 20, Issue 5, 2007, Pages 482-488

  Lawn, Stephen D ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Antiretroviral treatment; HAART; HIV AIDS; Immune restoration; IRIS; Parasite

Indexed keywords

AMPHOTERICIN B; ANTIRETROVIRUS AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; PRAZIQUANTEL;

CRYPTOSPORIDIOSIS; DISEASE ASSOCIATION; ENDEMIC DISEASE; HELMINTHIASIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMIGRANT; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LEISHMANIASIS; NONHUMAN; PARASITOSIS; REVIEW; SCHISTOSOMIASIS; STRONGYLOIDIASIS; TOXOPLASMOSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; PARASITIC DISEASES;

EID: 34548446278     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3282a6463d     Document Type: Review

References (41)

1. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
2. French MA. Disorders of immune reconstitution in patients with HIV infection responding to antiretroviral therapy. Curr HIV/AIDS Rep 2007; 4:16-21.
3. Shelburne SA III, Hamill RJ. The immune reconstitution inflammatory syndrome. AIDS Rev 2003; 5:67-79.
4. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004; 18:1615-1627.
5. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5:361-373.
6. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 2006; 42:418-427.
7. Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21:335-341.
8. Manosuthi W, Kiertiburanakul S, Phoorisri T, Sungkanuparph S. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. J Infect 2006; 53:357-363.
9. Puthanakit T, Oberdorfer P, Akarathum N, et al. Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected thai children. Pediatr Infect Dis J 2006; 25:53-58.
10. Lawn SD, French MA. Immune reconstitution disease: recent developments and implications for antiretroviral treatment in resource-limited settings. Curr Opin HIV AIDS 2007; 2:339-345.
11. Lawn SD, Bekker LG, Myer L, et al. Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS 2005; 19:2050-2052.
12. Lawn SD, Wilkinson RJ. Immune reconstitution disease associated with parasitic infections following antiretroviral treatment. Parasite Immunol 2006; 28:625-633. This is the first published review of immune reconstitution disease and parasitic infections.
13. Fernando R, Miller R. Immune reconstitution eosinophilia due to schistosomiasis. Sex Transm Infect 2002; 78:76.
14. de Silva S, Walsh J, Brown M. Symptomatic Schistosoma mansoni infection as an immune restoration phenomenon in a patient receiving antiretroviral therapy. Clin Infect Dis 2006; 42:303-304. This is the first case report of clinically significant IRD associated with schistosomiasis.
15. Javid B, Aliyu SH, Save VE, et al. Schistosomal colonic polyposis in an HIV-positive man. AIDS 2007; 21:386-388. This describes a possible case of IRD associated with schistosomiasis.
16. Kim AC, Lupatkin HC. Strongyloides stercoralis infection as a manifestation of immune restoration syndrome. Clin Infect Dis 2004; 39:439-440.
17. Lanzafame M, Faggian F, Lattuada E, et al. Strongyloidiasis in an HIV-1-infected patient after highly active antiretroviral therapy-induced immune restoration. J Infect Dis 2005; 191:1027.
18. Brown M, Cartledge JD, Miller RF. Dissemination of Strongyloides stercoralis as an immune restoration phenomenon in an HIV-1-infected man on antiretroviral therapy. Int J STD AIDS 2006; 17:560-561. This presents a possible case of IRD with strongyloidiasis complicated by E. coli meningitis.
19. Taylor CL, Subbarao V, Gayed S, Ustianowski AP. Immune reconstitution syndrome to Strongyloides stercoralis infection. AIDS 2007; 21:649-650. The authors describe a possible case of IRD with strongyloidiasis causing marked enteritis.
20. Albrecht H. Leishmaniosis: new perspectives on an underappreciated opportunistic infection. AIDS 1998; 12:2225-2226.
21. Jimenez-Exposito MJ, Alonso-Villaverde C, Sarda P, Masana L. Visceral leishmaniasis in HIV-infected patients with nondetectable HIV-1 viral load after highly active antiretroviral therapy. AIDS 1999; 13:152-153.
22. Berry A, Abraham B, Dereure J, et al. Two case reports of symptomatic visceral leishmaniasis in AIDS patients concomitant with immune reconstitution due to antiretroviral therapy. Scand J Infect Dis 2004; 36:225-227.
23. Posada-Vergara MP, Lindoso JA, Tolezano JE, et al. Tegumentary leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome in 2 patients with AIDS. J Infect Dis 2005; 192:1819-1822.
24. Kerob D, Bouaziz JD, Sarfati C, Pavie J, et al. First case of cutaneous reconstitution inflammatory syndrome associated with HIV infection and leishmaniasis. Clin Infect Dis 2006; 43:664-666. A case report of a Senegalese patient with cutaneous leishmaniasis who developed multiple subcutaneous nodules due to IRD during early ART.
25. Blanche P, Gombert B, Rivoal O, et al. Uveitis due to Leishmania major as part of HAART-induced immune restitution syndrome in a patient with AIDS. Clin Infect Dis 2002; 34:1279-1280.
26. Ridolfo AL, Gervasoni C, Antinori S, et al. Postkala-azar dermal leishmaniasis during highly active antiretroviral therapy in an AIDS patient infected with Leishmania infantum. J Infect 2000; 40:199-202.
27. Gilad J, Borer A, Hallel-Halevy D, Riesenberg K, et al. Postkala-azar dermal leishmaniasis manifesting after initiation of highly active antiretroviral therapy in a patient with human immunodeficiency virus infection. Isr Med Assoc J 2001; 3:451-452.
28. Jevtovic DJ, Salemovic D, Ranin J, et al. The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy. HIV Med 2005; 6:140-143.
29. Tsambiras PE, Larkin JA, Houston SH. Case report. Toxoplasma encephalitis after initiation of HAART. AIDS Read 2001; 11:608-616.
30. Subsai K, Kanoksri S, Siwaporn C, et al. Neurological complications in AIDS patients receiving HAART: a 2-year retrospective study. Eur J Neurol 2006; 13:233-239.
31. Plasencia LD, Socas MM, Valls RA, et al. Terminal ileitis as a manifestation of immune reconstitution syndrome following HAART. AIDS 2006; 20:1903-1905. This is the first case of IRD associated with cryptosporidiosis.
32. Montes M, White AC Jr, Kontoyiannis DP. Symptoms of intestinal schistosomiasis presenting during treatment of large B cell lymphoma. Am J Trop Med Hyg 2004; 71:552-553.
33. Mohamed SH, Kamel MM. Effect of cyclophosphamide-mediated immunodeficiency on murine Schistosomiasis mansoni. J Egypt Soc Parasitol 2000; 30:11-26.
34. Keiser PB, Nutman TB. Strongyloides stercoralis in the immunocompromised population. Clin Microbiol Rev 2004; 17:208-217.
35. Lucas SB. Missing infections in AIDS. Trans R Soc Trop Med Hyg 1990; 84 (Suppl 1):34-38.
36. Viney ME, Brown M, Omoding NE, et al. Why does HIV infection not lead to disseminated strongyloidiasis? J Infect Dis 2004; 190:2175-2180.
37. de la Rosa R, Pineda JA, Delgado J, et al. Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients. Clin Infect Dis 2001; 32:633-635.
38. Soong L, Chang CH, Sun J, et al. Role of CD4+ T cells in pathogenesis associated with Leishmania amazonensis infection. J Immunol 1997; 158:5374-5383.
39. Terabe M, Kuramochi T, Ito M, et al. CD4(+) cells are indispensable for ulcer development in murine cutaneous leishmaniasis. Infect Immun 2000; 68:4574-4577.
40. Meenken C, van Agtmael MA, Ten Kate RW, van den Horn GJ. Fulminant ocular leishmaniasis in an HIV-1-positive patient. AIDS 2004; 18:1485-1486.
41. World HealthOrganization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report, April 2007. Geneva: WHO; 2007. http://www.who.int/hiv/toronto2006/towardsuniversalaccess. pdf. [Accessed 24th April 2007]